There were no significant differences between the median plasma levels of IL-2 (9.0 vs. 9.81 pg/mL); IL-4 (126.24 vs. 146.78 pg/mL); IL-6 (10.52 vs. 10.4 pg/mL); IL-8 (9.61 vs. 9.81 pg/mL); IL-10 (42.76 vs. 47.61 pg/mL); IL-17A (23.05 vs. 23.92 pg/mL); and TGF-β1 (20353.26 vs. 23785.83 pg/mL) between early breast cancer patients compared to healthy controls. Here, CXCL8 is linked to breast carcinoma.